about
Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori.Proteome analysis of highly immunoreactive proteins of Helicobacter pylori.Clinical relevance of resistant strains of Helicobacter pylori: a review of current dataClarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates.Seroprevalence of helicobacter pylori in human immunodeficiency virus-positive Patients and it's correlation with CD4(+) Lymphocyte Count.Review article: nitroimidazole resistance in Helicobacter pylori.Seroprevalence of Helicobacter pylori in dyspeptic patients and its relationship with HIV infection, ABO blood groups and life style in a university hospital, Northwest EthiopiaCharacterisation of the genes encoding resistance to metronidazole (rdxA and frxA) and clarithromycin (the 23S-rRNA genes) in South African isolates of Helicobacter pylori.PCR using 3'-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pylori clinical isolates.Evaluation of clarithromycin resistance and cagA and vacA genotyping of Helicobacter pylori strains from the west of Ireland using line probe assays.Direct detection of Helicobacter pylori mutations associated with macrolide resistance in gastric biopsy material taken from human immunodeficiency virus-infected subjects.A randomized controlled comparison of three quadruple therapy regimens in a population with low Helicobacter pylori eradication rates.Absence of Helicobacter pylori high tetracycline resistant 16S rDNA AGA926-928TTC genotype in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil.Clinical trial report: Eradication of Helicobacter pylori reduces the risk for subsequent gastric cancer.Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran.A Comparison between Moderate- and High-dose Furazolidone in Triple Regimens for Helicobacterpylori Eradication in IranHigh prevalence of clarithromycin resistance and cagA, vacA, iceA2, and babA2 genotypes of Helicobacter pylori in Brazilian childrenShort-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori.Bactericidal activity of Pistacia lentiscus mastic gum against Helicobacter pylori.Low rate of recurrence of Helicobacter pylori infection in spite of high clarithromycin resistance in Pakistan.Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.Detection of clarithromycin-resistant Helicobacter pylori in stool samples.Type 2 diabetes mellitus affects eradication rate of Helicobacter pyloriHelicobacter pylori in Iran: A systematic review on the association of genotypes and gastroduodenal diseases.The incidence of primary antibiotic resistance of Helicobacter pylori in VietnamTreatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic.Clinical role and importance of fluorescence in situ hybridization method in diagnosis of H pylori infection and determination of clarithromycin resistance in H pylori eradication therapy.Metronidazole-resistant Helicobacter pylori is more prevalent in patients with nonulcer dyspepsia than in peptic ulcer patients in a multiethnic Asian populationAntibiotics resistance rate of Helicobacter pylori in BhutanA randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian NorthGastric infection by Helicobacter pylori.Alhagi: a plant genus rich in bioactives for pharmaceuticals.Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication.Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection.Growth supplements for Helicobacter pylori.Subpopulations of Helicobacter pylori are responsible for discrepancies in the outcome of nitroimidazole susceptibility testing.Rapid detection, by PCR and reverse hybridization, of mutations in the Helicobacter pylori 23S rRNA gene, associated with macrolide resistance.Sensitivity of amoxicillin-resistant Helicobacter pylori to other penicillins.
P2860
Q30680936-0CA28A1F-D758-4313-A8EA-5312F1D9F0C2Q31067940-2F7D5D72-D859-464D-935F-E9EE3532C91FQ32003780-AABEB078-834D-4F9C-BD7B-7516042200C8Q32026744-24B38545-DCDC-4388-8F0E-B225FFED9A56Q32090384-D36EF8DC-1739-4A18-9D35-5454B96FA46BQ33723548-DE1E077D-745A-428D-997F-4688E9F25941Q33809297-C5C480AD-6BAE-4CA5-B99E-4B788B9CD08EQ33815739-BBA2510B-2B8C-440D-9295-1A647D73EB0CQ33866632-0A851D87-DB61-490E-949C-5C7A9AA70579Q33877642-31DD5BE6-E60D-44F8-8919-E195160C897DQ33965705-CBACB055-4E71-42C6-A4C7-3B427731EDEDQ33972380-3B2E5676-A611-42BF-A44F-76035C8D4CC5Q34195188-6E557D92-02F4-49D9-A7A7-7662F91F8C13Q34242765-82DFA496-E92C-4685-8B92-3ADB86A08291Q34272391-211C6AB2-FCE0-4090-8541-07D8D2078E13Q34280623-4148FFB4-CD48-431E-A73D-F5E0B19B4318Q34385180-D74BEF34-BBDA-4604-BB66-AA5AC93FA47FQ34401441-C88AC394-75D8-4205-8879-5283489285FEQ34489491-8E20C0BA-5E49-4F57-A280-8EFA4DB78239Q34501295-8F7A4ABE-3571-4B48-BF4E-223FD8DF12A6Q34520547-2F4D3C54-BB0A-460A-973A-70E1485BE3E5Q34596762-160A2196-C57B-40DF-9FA5-88B8D4415701Q35011360-A46DA0DB-6BC8-46B2-84D6-4B75214645F5Q35636188-B1666366-9768-4743-8318-972C5C682CE5Q36178510-2AD2E3F8-2E51-47A3-9556-D1666445291EQ36479958-2F8032A7-742F-4D03-83B6-642ABC07D86EQ36565896-C6E0D722-F832-4846-9EA4-014A9D0596F7Q36723844-4B809D1F-F169-4A58-94B0-260F6AF22A4EQ36728105-2D40C630-9F56-456B-A1CF-1E7704C3F614Q37059284-321FC7F2-E532-42D3-8C81-022D4BDD2ADAQ37142225-5D34814C-3599-4B20-B168-A3E2B8F78DE8Q37558559-B0229B0C-058B-4213-B6E5-B70E2F484621Q37630727-D1D82C35-46F2-43C2-BB47-E7D469EA3C22Q38254407-62528152-91B2-47FD-AA77-10C1523131B3Q38502899-2A5ABBBD-7BFC-49EB-9A3B-880A9A92C7D4Q39316784-E10964CD-FDCF-421C-9627-7F0F35CF229CQ39457560-2BC44445-957F-46CF-8975-3DAD43BB5715Q39470987-B9CEA94D-E2C3-4921-80B1-2D49AF6BEF8BQ39471335-9CE88647-3509-4636-9D33-B57B9D34645CQ39471361-666AA868-22C1-4ECC-B730-63866636D561
P2860
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Resistance of Helicobacter pylori to antibiotics.
@en
type
label
Resistance of Helicobacter pylori to antibiotics.
@en
prefLabel
Resistance of Helicobacter pylori to antibiotics.
@en
P1476
Resistance of Helicobacter pylori to antibiotics.
@en
P2093
P356
10.1046/J.1365-2036.11.S1.11.X
P407
P478
11 Suppl 1
P577
1997-04-01T00:00:00Z